1
|
Koita OA, Sangaré L, Miller HD, Sissako A, Coulibaly M, Thompson TA, Fongoro S, Diarra Y, Ba M, Maiga A, Diallo B, Mushatt DM, Mather FJ, Shaffer JG, Anwar AH, Krogstad DJ. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. THE LANCET. INFECTIOUS DISEASES 2017; 17:1266-1275. [PMID: 28916443 PMCID: PMC5700806 DOI: 10.1016/s1473-3099(17)30365-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 05/16/2017] [Accepted: 06/08/2017] [Indexed: 12/02/2022]
Abstract
BACKGROUND Chloroquine was used for malaria treatment until resistant Plasmodium falciparum was identified. Because 4-aminoquinolines with modified side chains, such as AQ-13, are active against resistant parasites, we compared AQ-13 against artemether plus lumefantrine for treatment of uncomplicated P falciparum malaria. METHODS We did a randomised, non-inferiority trial. We screened men (≥18 years) with uncomplicated malaria in Missira (northeast Mali) and Bamako (capital of Mali) for eligibility (≥2000 asexual P falciparum parasites per μL of blood). Eligible participants were randomly assigned to either the artemether plus lumefantrine group or AQ-13 group by permuting blocks of four with a random number generator. Physicians and others caring for the participants were masked, except for participants who received treatment and the research pharmacist who implemented the randomisation and provided treatment. Participants received either 80 mg of oral artemether and 480 mg of oral lumefantrine twice daily for 3 days or 638·50 mg of AQ-13 base (two oral capsules) on days 1 and 2, and 319·25 mg base (one oral capsule) on day 3. Participants were monitored for parasite clearance (50 μL blood samples twice daily at 12 h intervals until two consecutive negative samples were obtained) and interviewed for adverse events (once every day) as inpatients during week 1. During the 5-week outpatient follow-up, participants were examined for adverse events and recurrent infection twice per week. All participants were included in the intention-to-treat analysis and per-protocol analysis, except for those who dropped out in the per-protocol analysis. The composite primary outcome was clearance of asexual parasites and fever by day 7, and absence of recrudescent infection by parasites with the same molecular markers from days 8 to 42 (defined as cure). Non-inferiority was considered established if the proportion of patients who were cured was higher for artemether plus lumefantrine than for AQ-13 and the upper limit of the 95% CI was less than the non-inferiority margin of 15%. This trial is registered at ClinicalTrials.gov, number NCT01614964. FINDINGS Between Aug 6 and Nov 18, 2013, and between Sept 18 and Nov 20, 2015, 66 Malian men with uncomplicated malaria were enrolled. 33 participants were randomly assigned to each group. There were no serious adverse events (grade 2-4) and asexual parasites were cleared by day 7 in both groups. 453 less-severe adverse events (≤grade 1) were reported: 214 in the combination group and 239 in the AQ-13 group. Two participants withdrew from the AQ-13 group after parasite clearance and three were lost to follow-up. In the artemether plus lumefantrine group, two participants had late treatment failures (same markers as original isolates). On the basis of the per-protocol analysis, the AQ-13 and artemether plus lumefantrine groups had similar proportions cured (28 [100%] of 28 vs 31 [93·9%] of 33; p=0·50) and AQ-13 was not inferior to artemether plus lumefantrine (difference -6·1%, 95% CI -14·7 to 2·4). Proportions cured were also similar between the groups in the intention-to-treat analysis (28 of 33, 84·8% for AQ-13 vs 31 of 33, 93·9% for artemether and lumefantrine; p=0·43) but the upper bound of the 95% CI exceeded the 15% non-inferiority margin (difference 9·1%, 95% CI -5·6 to 23·8). INTERPRETATION The per-protocol analysis suggested non-inferiority of AQ-13 to artemether plus lumefantrine. By contrast, the intention-to-treat analysis, which included two participants who withdrew and three who were lost to follow-up from the AQ-13 group, did not meet the criterion for non-inferiority of AQ-13, although there were no AQ-13 treatment failures. Studies with more participants (and non-immune participants) are needed to decide whether widespread use of modified 4-aminoquinolones should be recommended. FUNDING US Food and Drug Administration Orphan Product Development, National Institutes of Health, US Centers for Disease Control and Prevention, Burroughs-Wellcome Fund, US State Department, and WHO.
Collapse
Affiliation(s)
- Ousmane A Koita
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Lansana Sangaré
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Haiyan D Miller
- Department of Tropical Medicine and the Center for Infectious Diseases, Tulane University Health Sciences Center, New Orleans, LA, USA
| | - Aliou Sissako
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Moctar Coulibaly
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Trevor A Thompson
- Department of Tropical Medicine and the Center for Infectious Diseases, Tulane University Health Sciences Center, New Orleans, LA, USA
| | - Saharé Fongoro
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Youssouf Diarra
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Mamadou Ba
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Ababacar Maiga
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Boubakar Diallo
- University of the Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - David M Mushatt
- Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
| | - Frances J Mather
- Department of Global Biostatistics and Data Science, Tulane University Health Sciences Center, New Orleans, LA, USA
| | - Jeffrey G Shaffer
- Department of Global Biostatistics and Data Science, Tulane University Health Sciences Center, New Orleans, LA, USA
| | - Asif H Anwar
- Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
| | - Donald J Krogstad
- Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA; Department of Tropical Medicine and the Center for Infectious Diseases, Tulane University Health Sciences Center, New Orleans, LA, USA.
| |
Collapse
|
2
|
Geary TG, Divo AD, Jensen JB, Zangwill M, Ginsburg H. Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro. Implications for mechanism of action of and resistance to the drug. Biochem Pharmacol 1990; 40:685-91. [PMID: 2201299 DOI: 10.1016/0006-2952(90)90302-2] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The antimalarial mode of action of chloroquine (CQ) has been investigated in great detail in recent years, but the overall mechanism is still controversial. Instead of further probing the molecular aspects of partial reactions, a model based on the weak base properties of CQ and its delta pH-driven accumulation in acid parasite compartments has been devised, and the integrated response of the parasite to the drug under different experimental conditions has been assayed to verify the validity of the model. Factors such as inoculum size (parasitemia.hematocrit) and medium pH were altered using CQ-sensitive (FCC1) and -resistant (FCR3, VNS) isolates of Plasmodium falciparum. Experimental results were in full agreement with the predictions of the model, implying that therapeutic concentrations of CQ do not raise the pH of the food vacuole, i.e. that alkalinization of the acid parasite compartments is an insufficient explanation for the antimalarial activity of CQ, and that there is no need to invoke an active QC efflux pump to explain drug resistance. Calculations based on the model and the experimental data demonstrate that resistance to CQ is correlated with higher pH and/or higher resistance of the intracellular target to the drug concentration in the parasite food vacuole. The data also have implications for the design and interpretation of in vitro CQ inhibitory tests.
Collapse
Affiliation(s)
- T G Geary
- Department of Microbiology and Public Health, Michigan State University, East Lansing 48824-1101
| | | | | | | | | |
Collapse
|
4
|
Watkins WM, Sixsmith DG, Spencer HC, Boriga DA, Kariuki DM, Kipingor T, Koech DK. Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya. Lancet 1984; 1:357-9. [PMID: 6141423 DOI: 10.1016/s0140-6736(84)90410-0] [Citation(s) in RCA: 122] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Studies were conducted in Malindi, Kenya, to assess the response of Plasmodium falciparum to chloroquine and amodiaquine in vivo (by an extended 14-day test) and in vitro (with the Rieckmann micro test). In-vivo resistance was demonstrated in 19 of 69 (28%) infections treated with chloroquine, but in only 2 of 60 (3.3%) of those treated with amodiaquine (p less than 0.001). In-vitro resistance to chloroquine was demonstrated in 15 of 23 (65%) tests. In contrast, 22 of the same 23 isolates were sensitive to amodiaquine in vitro. Effective concentrations by probit analysis for 50% and 99% (EC50 and EC99) inhibition, respectively, were 180.7 and 4319.6 nmol/l for chloroquine and 12.2 and 147.0 nmol/l for amodiaquine. The results suggest that amodiaquine is effective for the treatment of chloroquine-resistant falciparum malaria in Kenya.
Collapse
|